Neutrophil-to-lymphocyte ratio as a predictor of overall survival and cancer advancement in patients undergoing radical cystectomy for bladder cancer.

bladder cancer inflammation neutrophil-lymphocyte ratio

Journal

Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101

Informations de publication

Date de publication:
2022
Historique:
received: 14 11 2021
revised: 30 12 2021
accepted: 03 01 2022
entrez: 20 5 2022
pubmed: 21 5 2022
medline: 21 5 2022
Statut: ppublish

Résumé

Neutrophil-to-lymphocyte ratio (NLR) has proven to be promising as a prognostic factor in many malignancies. We investigated the prognostic significance of NLR in patients undergoing radical cystectomy (RC) for bladder cancer (BC). We retrospectively evaluated the data of 134 consecutive patients with BC who underwent RC between 2011 and 2017 at a single center. Overall survival (OS) was assessed using the Kaplan-Meier method and compared between NLR subpopulations using the log-rank test. Univariate and multivariate Cox proportional hazard models were used to identify the variables affecting OS. At a median follow-up of 2.2 years, high NLR (>2.7) correlated with worse a survival outcome (p = 0.0345 in log-rank test), higher tumor stage (p = 0.0047), and higher frequency of positive lymph nodes (p = 0.0285). The univariate model showed that a high NLR (p = 0.038528), advanced pathological tumor stage (p = 0.000763), lymph node involvement (p = 0.013384), a high grade of cancer (p = 0.015611), lymphovascular invasion (LVI) (p = 0.001530), positive margins (p = 0.000890) and ureterocutaneostomy as urinary diversion (p = 0.038854) had a negative impact on OS. Tumor extending beyond the submucosa (>pT1) (hazard ratio 2.161, confidence interval 1058-4411, p = 0.0345) and lymphatic infiltration (hazard ratio 1.599, confidence interval 1028-2482, p = 0.037) have been recognized as independent risk factors of poor prognosis in multivariate Cox regression analysis. In our cohort, an elevated NLR is associated with worse OS and adverse histopathological findings. Consequently, the NLR is an easily acquired biomarker, which may be useful in pretreatment patient risk stratification.

Identifiants

pubmed: 35591971
doi: 10.5173/ceju.2022.0273
pii: 0273
pmc: PMC9074069
doi:

Types de publication

Journal Article

Langues

eng

Pagination

41-46

Informations de copyright

Copyright by Polish Urological Association.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Clin Cancer Res. 2009 Jan 15;15(2):425-30
pubmed: 19147746
Urologe A. 2012 Sep;51(9):1220-7
pubmed: 22434483
Nat Rev Immunol. 2004 Aug;4(8):641-8
pubmed: 15286730
Clin Genitourin Cancer. 2016 Dec;14(6):473-484
pubmed: 27209348
Asian J Urol. 2017 Oct;4(4):239-246
pubmed: 29387556
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Arab J Urol. 2020 Aug 26;19(1):2-8
pubmed: 33763243
Lancet. 2009 Jul 18;374(9685):239-49
pubmed: 19520422
Eur J Cancer. 2008 May;44(7):946-53
pubmed: 18396036
Immunobiology. 2013 Nov;218(11):1402-10
pubmed: 23891329
Eur Urol. 2014 Dec;66(6):1157-64
pubmed: 24630414
Gastric Cancer. 2011 Aug;14(3):266-73
pubmed: 21505767
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Epidemiol. 2013 Jun;37(3):219-25
pubmed: 23485480
J Endourol. 2013 Aug;27(8):1046-50
pubmed: 23517015
Eur Urol Focus. 2016 Apr;2(1):79-85
pubmed: 28723455
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Nat Rev Urol. 2016 Aug;13(8):471-9
pubmed: 27431340
Cancer Metastasis Rev. 2008 Mar;27(1):11-8
pubmed: 18066650
Mol Cancer Res. 2006 Apr;4(4):221-33
pubmed: 16603636
Future Oncol. 2010 Jan;6(1):149-63
pubmed: 20021215
Int J Colorectal Dis. 2012 Oct;27(10):1347-57
pubmed: 22460305
Clin Genitourin Cancer. 2015 Aug;13(4):e229-e233
pubmed: 25777682
Eur Urol. 2017 Mar;71(3):437-446
pubmed: 28029399
Urol Oncol. 2020 Jan;38(1):3.e17-3.e27
pubmed: 31676278
Expert Rev Cardiovasc Ther. 2016;14(5):573-7
pubmed: 26878164
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Oncotarget. 2017 Mar 7;8(10):17258-17269
pubmed: 27791991
J Surg Oncol. 2003 Aug;83(4):248-52
pubmed: 12884238
Medicine (Baltimore). 2015 Oct;94(40):e1670
pubmed: 26448011
Urol J. 2020 Jan 26;17(1):30-35
pubmed: 31087321
J Oncol Pract. 2017 Sep;13(9):621-625
pubmed: 28796558

Auteurs

Damian Sudoł (D)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Damian Widz (D)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Przemysław Mitura (P)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Paweł Płaza (P)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Michał Godzisz (M)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Iga Kuliniec (I)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Andriy Yadlos (A)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Michał Cabanek (M)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Marek Bar (M)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Krzysztof Bar (K)

Department of Urology and Oncological Urology, Medical University of Lublin, Lublin, Poland.

Classifications MeSH